[144] Marex Group plc SEC Filing

Rhea-AI Filing Summary

Marex Group plc (MRX) filed a Form 144 reporting a proposed sale of 56,000 common shares through Goldman Sachs & Co. LLC with an aggregate market value of $1,631,840. The filing shows approximately 71,231,706 shares outstanding and lists an approximate sale date of 10/06/2025. The shares were acquired on 04/29/2016 as restricted stock units paid as compensation. The filer previously sold three blocks of 14,000 shares each on 07/07/2025, 08/04/2025, and 09/02/2025 for gross proceeds of $545,115.20, $530,272.40, and $488,163.20, respectively. The notice includes the standard representation that the seller does not possess undisclosed material information and references Rule 10b5-1 trading-plan language.

Positive

• Clear disclosure of broker (Goldman Sachs) and sale amount (56,000 shares)
• Securities were acquired as compensation (restricted stock units dated 04/29/2016), providing provenance

Negative

• Ongoing insider selling pattern: three prior sales of 14,000 shares each in 07/07/2025, 08/04/2025, and 09/02/2025
• Sale represents ~0.08% of outstanding shares (56,000 of 71,231,706), indicating limited liquidity impact but continued supply pressure

Insights

Equity Capital Markets Analyst

TL;DR: Officer/insider sale of 56,000 shares via broker; prior small block sales occurred in the past three months.

The filing reports a planned disposition of 56,000 common shares valued at $1,631,840 to be executed through Goldman Sachs on or about 10/06/2025. The shares originated from restricted stock units granted on 04/29/2016, indicating these are compensation-related holdings being liquidated.

Material dependencies include the actual execution of the trades and public-market liquidity given ~71.2M shares outstanding; the filing also notes prior sales of 14,000-share blocks in 07/07/2025, 08/04/2025, and 09/02/2025, showing an ongoing disposal pattern. Monitor settlement of the listed trades within days of the stated sale date.

Corporate Governance Specialist

TL;DR: Form 144 includes the seller's attestation regarding undisclosed material information and references Rule 10b5-1 considerations.

The signer certifies they are unaware of undisclosed material facts and the form provides space to note a Rule 10b5-1 plan adoption date if applicable. The disclosure of acquisition as compensation and the broker name are standard governance details that support transparency around insider sales.

Key items to watch are whether a dated 10b5-1 plan is disclosed and whether additional Form 4 or Form 144 filings follow shortly after 10/06/2025, which would clarify timing and adherence to trading policies.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Goldman Sachs & Co. LLC 200 West Street New York NY 10282	56000	1631840	71231706	10/06/2025	NASD

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	04/29/2016	Acquired as compensation -- Restricted Stock Units	The Issuer			56000	04/29/2016	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Simon Van Den Born 155 Bishopsgate London X0 EC2M 3TQ	Common Stock	09/02/2025	14000	488163.2
Simon Van Den Born 155 Bishopsgate London X0 EC2M 3TQ	Common Stock	07/07/2025	14000	545115.2
Simon Van Den Born 155 Bishopsgate London X0 EC2M 3TQ	Common Stock	08/04/2025	14000	530272.4

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Marex Group (MRX) report in the Form 144?

The filing reports a proposed sale of 56,000 common shares through Goldman Sachs with an aggregate market value of $1,631,840 and an approximate sale date of 10/06/2025.

When were the shares being sold originally acquired?

The shares were acquired on 04/29/2016 as restricted stock units issued as compensation.

Has the filer sold shares recently before this Form 144?

Yes. The filer sold three blocks of 14,000 shares on 07/07/2025, 08/04/2025, and 09/02/2025 for gross proceeds of $545,115.20, $530,272.40, and $488,163.20, respectively.

Who is the broker handling the planned sale?

The broker named in the filing is Goldman Sachs & Co. LLC, located at 200 West Street, New York, NY.

Does the filing state the filer has undisclosed material information?

By signing, the filer represents they do not know any undisclosed material adverse information; the form also references Rule 10b5-1 plan language if applicable.